EGFR-TKI靶向治疗对Ⅳ期非小细胞肺癌患者肿瘤标志物、免疫功能及血清VEGF水平的影响  

Effects of EGFR-TKI targeted therapy on tumor markers,immune function and serum VEGF level in patients with stageⅣnon-small cell lung cancer

作　　者：李玉亮 李衎 杨庆辉 Li Yuliang;Li Kan;Yang Qinghui

机构地区：[1]汤阴县人民医院肿瘤内科,456150 [2]安阳市肿瘤医院(河南科技大学第四附属医院)胸外四科,455000 [3]新乡市医学院第一附属医院放射治疗二病区,453000

出　　处：《中国疗养医学》2022年第2期137-139,共3页Chinese Journal of Convalescent Medicine

摘　　要：目的观察Ⅳ期非小细胞肺癌(NSCLC)患者应用表皮生长因子酪氨酸激酶抑制剂(EGFR-TKI)靶向治疗后的免疫功能、肿瘤标志物水平和血清相关指标的变化。方法选取汤阴县人民医院肿瘤内科2019年2月至2020年12月收治的83例Ⅳ期NSCLC患者作为研究对象,抽签法分组,对照组41例给予传统化疗,观察组42例给予EGFR-TKI靶向治疗,对比两组的肿瘤标志物、免疫功能和血清生化指标。结果治疗后,观察组鳞状细胞癌抗原(SCC)水平为(1.10±0.22)μg/L,低于对照组的(1.82±0.27)μg/L,癌胚抗原(CEA)水平为(30.76±9.27)μg/L,低于对照组的(38.85±10.13)μg/L,细胞角蛋白19片段(CYFRA21-1)水平为(7.14±1.90)μg/L,低于对照组的(11.79±2.13)μg/L,P<0.05;观察组血管内皮生长因子(VEGF)水平为(0.28±0.04)ng/L,低于对照组的(0.44±0.06)ng/L,基质金属蛋白酶9(MMP-9)水平为(1.10±0.10)ng/L,低于对照组的(1.34±0.12)ng/L、神经元特异性烯醇化酶(NSE)水平为(12.17±2.47)ng/mL,低于对照组的(17.52±2.60)ng/mL,P<0.05;观察组表面抗原分化簇8(CD_(8)^(+))水平低于对照组,表面抗原分化簇3(CD_(3)^(+))、表面抗原分化簇4(CD_(4)^(+))水平高于对照组,P<0.05。结论EGFR-TKI靶向治疗NSCLC临床效果佳,免疫功能、肿瘤标志物和血清相关指标均得到改善。Objective To observe the changes of immune function,tumor marker level and serum related indexes in patients with stage IV non-small cell lung cancer(NSCLC)after targeted treatment with epidermal growth factor receptor-tyrosine kinase inhibitor(EGFR-TKI).Methods 83 patients with stage IV NSCLC treated in the Department of oncology of Tangyin County People's Hospital from February 2019 to December 2020 were selected as the research objects.41 patients in the control group were given traditional chemotherapy and 42 patients in the observation group were given EGFR-TKI targeted therapy.The tumor markers,immune function and serum biochemical indexes of the two groups were compared.Results After treatment,the level of squamous cell carcinoma antigen(SCC)in the observation group was(1.10±0.22)μg/L,lower than that of the control group(1.82±0.27)μg/L,the level of carcinoembryonic antigen(CEA)was(30.76±9.27)μg/L,lower than that of the control group(38.85±10.13)μg/L,the level of cytokeratin 19 fragment(CYFRA21-1)was(7.14±1.90)μg/L,lower than that of the control group(11.79±2.13)μg/L,P<0.05;The level of vascular endothelial growth factor(VEGF)in the observation group was(0.28±0.04)ng/L,lower than that in the control group(0.44±0.06)ng/L,the level of matrix metalloproteinase-9(MMP-9)was(1.10±0.10)ng/L,lower than that in the control group(1.34±0.12)ng/L,and the level of neuron specific enolase(NSE)was(12.17±2.47)ng/mL,lower than that in the control group(17.52±2.60)ng/mL,P<0.05;The levels of surface antigen cluster of differentiation 8(CD8+)in the observation group were lower than those in the control group,and the levels of surface antigen cluster of differentiation 3(CD_(3)^(+))and surface antigen cluster of differentiation 4(CD_(4)^(+))in the observation group were higher than those in the control group(P<0.05).Conclusion The clinical effect of EGFR-TKI targeted therapy in patients with NSCLC is good,and the immune function,tumor markers and serum related indexes are improved.

关 键 词：非小细胞肺癌 表皮生长因子酪氨酸激酶抑制剂 化疗 

分 类 号：R734.2[医药卫生—肿瘤]